JP2023527775A5 - - Google Patents
Info
- Publication number
- JP2023527775A5 JP2023527775A5 JP2022571133A JP2022571133A JP2023527775A5 JP 2023527775 A5 JP2023527775 A5 JP 2023527775A5 JP 2022571133 A JP2022571133 A JP 2022571133A JP 2022571133 A JP2022571133 A JP 2022571133A JP 2023527775 A5 JP2023527775 A5 JP 2023527775A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US63/029,085 | 2020-05-22 | ||
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US63/066,705 | 2020-08-17 | ||
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US63/071,264 | 2020-08-27 | ||
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US63/088,147 | 2020-10-06 | ||
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US63/121,088 | 2020-12-03 | ||
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| US63/144,939 | 2021-02-02 | ||
| EP21315068 | 2021-04-21 | ||
| EP21315068.3 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527775A JP2023527775A (ja) | 2023-06-30 |
| JP2023527775A5 true JP2023527775A5 (https=) | 2024-05-28 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571133A Pending JP2023527775A (ja) | 2020-05-22 | 2021-05-21 | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (https=) |
| EP (1) | EP4153300A1 (https=) |
| JP (1) | JP2023527775A (https=) |
| KR (1) | KR20230015965A (https=) |
| CN (1) | CN115768516A (https=) |
| AU (1) | AU2021277398A1 (https=) |
| BR (1) | BR112022022235A2 (https=) |
| CA (1) | CA3174431A1 (https=) |
| IL (1) | IL298257A (https=) |
| MX (1) | MX2022014440A (https=) |
| WO (1) | WO2021237110A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| HUE067888T2 (hu) | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CA3246860A1 (en) * | 2022-04-26 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | TRANSCRIPTOME ANALYSIS FOR THE TREATMENT OF INFLAMMATION |
| KR20250037491A (ko) | 2022-07-08 | 2025-03-17 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제 투여에 의한 소아 호산구성 식도염을 치료하는 방법 |
| EP4688142A1 (en) | 2023-03-27 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| JP6871948B2 (ja) * | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) * | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US11053309B2 (en) * | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| CA3090832A1 (en) * | 2018-02-21 | 2019-08-29 | Adare Pharmaceuticals Us, L.P. | Methods of managing eosinophilic esophagitis |
| JPWO2019240288A1 (ja) * | 2018-06-14 | 2021-07-26 | 味の素株式会社 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527775A5 (https=) | ||
| US12059494B2 (en) | Methods of treating eosinophilic esophagitis | |
| KR102345816B1 (ko) | 코 투여 | |
| KR101873174B1 (ko) | 날록손을 포함하는 비강내 제약 투여 형태 | |
| US20200206227A1 (en) | Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof | |
| US8642069B2 (en) | Composition and method for treating colds | |
| JP2023537403A5 (https=) | ||
| CN105792828A (zh) | 使用莫米松和奥洛他定的组合治疗过敏性鼻炎 | |
| Peerbhay et al. | Intranasal midazolam sedation in a pediatric emergency dental clinic | |
| JP7090124B2 (ja) | 経鼻投与 | |
| Shanmugaavel et al. | Comparison of behavior and dental anxiety during intranasal and sublingual midazolam sedation–a randomized controlled trial | |
| WO2008087437A1 (en) | Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809) | |
| JP2024532263A5 (https=) | ||
| CN102143686A (zh) | 用4-氨基吡啶持续治疗脱髓鞘病患者 | |
| Phillips et al. | A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers | |
| Swain et al. | Current treatment options for allergic rhinitis: a review | |
| JP2020522524A5 (https=) | ||
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| Bhagat et al. | Physicians perception in the management of allergic rhinitis: a Pan-India survey | |
| CN116801863A (zh) | 右美托咪定治疗方案 | |
| EP4236988A1 (en) | Intranasal immunotherapy for the treatment of alzheimer's disease | |
| Colice | Emerging therapeutic options for asthma | |
| JP2021514947A (ja) | モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療 | |
| US20210330900A1 (en) | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) | |
| WO2026078117A1 (en) | Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps |